-
Ascletis announces that its clinical trial application for the oral PD-L1 small molecule inhibitor ASC61 for the treatment of advanced solid tumors has been approved by the China National Food
Time of Update: 2023-01-01
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that ASC61, an oral small molecule inhibitor of oral PD-L1, has been approved by the National Medical Products Administration (NMPA) of China (NMPA) for a New Drug Clinical Trial (IND) application for the treatment of advanced solid tumors.
-
Shanghai Chengsi Protective Mask Air Tightness Tester Technical exchange and experience
Time of Update: 2022-10-03
Protective mask airtightness tester respirator as a respiratory protection equipment required in the field of medical protection, the type of mask can be mainly divided into disposable masks, replacea
-
Local innovative drug companies join forces to actively explore clinical value
Time of Update: 2022-09-30
In China, the drug has completed two Phase III clinical studies of duodenal ulcer and gastroesophageal reflux, and submitted a marketing application for 2 indications to the State Food and Drug Administration in September 2021, and is currently undergoing review and approval.
-
Yangtze River's big move
Time of Update: 2021-11-05
Currently, 15 innovative drugs (14 are category 1 new drugs) are in the clinical application and above stage; 79 have been reviewed The varieties (22 are the first ones) are eye-catching, helping the company to harvest a lot in centralized procurement; 76 new classifications are under review, and 20 have not been approved for the first copy .
-
The Market Supervision Department of Ningxia Hui Autonomous Region strengthens the random inspection and testing of illegal addition of non-edible substances in catering food
Time of Update: 2021-11-01
Supervise food production, catering, special rectification, food safety supervision, illegal addition of non-edible substances, hot pot sampling inspection, food seasoning inspection Up to now, 194 batches of sampling and testing have been completed , including 64 batches of hot pot seasonings and 130 batches of soups, with a pass rate of 100%, and no illegal additions have been found .
-
Tengshengbo Pharmaceutical submitted an emergency use authorization application for the new crown neutralizing antibody to the FDA, which has better efficacy than small molecule drugs
Time of Update: 2021-10-22
Currently, the new crown neutralizing antibody BRII-196/BRII-198 "cocktail" therapy is undergoing phase 3 clinical trials in multiple centers around the world .
-
Hengrui Medicine's 3 new drugs approved for clinical treatment of diabetes and tumors
Time of Update: 2021-09-05
According to the latest announcement by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Hengrui Medicine's three new biological drugs have recently obtained
-
Tianyan announced the third clinical trial cooperation with Merck
Time of Update: 2021-08-26
On August 19th, Tianyan Pharmaceutical (NASDAQ: ADAG) announced that it had reached a third clinical trial cooperation agreement with Merck & Co.
The two parties will initiate an open-label, dose escalation and extended study clinical trial (ADG106-P2001/KEYNOTE- D12) to evaluate the clinical efficacy of the combination in patients with advanced or metastatic solid and/or hematological malignancies .
-
Biotech, which is hitting the three-inch recharge, will be cleaned up
Time of Update: 2021-08-08
Text | CloverLast Friday, CDE's notice of opinions on the "Clinical Value-Oriented Anti-tumor Drug Clinical Research and Development Guidelines" (hereinafter referred to as the "Guiding Principles") triggered a "big shock" and heated discussions in the pharmaceutical industry .
-
The first class 1 new drug
Time of Update: 2021-07-31
Text | plus oneOn July 24, the CDE official website showed that Qilu Pharmaceutical submitted and accepted a listing application for a new class 1 drug "Yiluok Tablets" .
-
Immunity: "harmful" fat may inhibit the body's ability to attack cancer cells by killer T cells
Time of Update: 2021-06-22
Recently, in a research report titled "Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors" published in the international journal Immunity , scientists from Salk Institute and other institutions Studies have found that the tumor microenvironment contains a large number of oxidized lipid molecules.
-
New Drug Development: Anti-HER3 Targeted Therapy 30 Years of Creeping Road
Time of Update: 2021-04-27
The pan-HER family inhibitor Sym013 is a mixture of six humanized full-length monoclonal antibodies against three targets of EGFR, HER2, and HER3, and has been shown to reduce the growth of cancer cells in vivo and in vitro.
-
JCC: Analysis of the effectiveness and safety of Ustekinumab in ulcerative colitis
Time of Update: 2021-04-22
. Figure: Changes in the efficacy of Ulsinumumab in the treatment of ulcerative colitis This study confirms that Ustekinumab has a good effect on alleviating disease activity in real life, both in the short and long term, but a higher burden of inflammation at baseline is associated with a lower probability of remission.
-
The application for clinical trial of the MCLA-129 injectable drug from Beda Pharmaceuticals was accepted
Time of Update: 2021-01-24
As of the date of disclosure of this announcement, Johnson and Johnson's EGFR/c-Met dual-specific antibody Amivantamab filed a Biological Product Licensing Application (BLA) and Marketing Authorization Application (MAA) with the FDA and the European EMA in December 2020, respectively, for the treatment of metastasis non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
-
Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically
Time of Update: 2021-01-19
Insight data show that most of the c-MET targeted drugs currently under study in China are small molecule drugs, and only 4 antibody drugs are currently in clinical stage, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection.
